Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Author:

Tawbi Hussein A.1ORCID,Schadendorf Dirk1ORCID,Lipson Evan J.1,Ascierto Paolo A.1ORCID,Matamala Luis1,Castillo Gutiérrez Erika1,Rutkowski Piotr1,Gogas Helen J.1,Lao Christopher D.1,De Menezes Juliana Janoski1,Dalle Stéphane1,Arance Ana1,Grob Jean-Jacques1,Srivastava Shivani1,Abaskharoun Mena1,Hamilton Melissa1,Keidel Sarah1,Simonsen Katy L.1,Sobiesk Anne Marie1,Li Bin1,Hodi F. Stephen1,Long Georgina V.1ORCID

Affiliation:

1. From the Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston (H.A.T.); the Department of Dermatology, University Hospital Essen, and the German Cancer Consortium, Essen, Germany (D.S.); the Sidney Kimmel Comprehensive Cancer Center, Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore (E.J.L.); Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale,” Naples, Italy (P.A.A.);...

Funder

Bristol-Myers Squibb

Publisher

Massachusetts Medical Society

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3